top of page

Inflection Biosciences Announces Research Collaboration with MD Anderson Cancer Center.

Updated: Mar 19, 2021

Dublin, Ireland, November 1, 2018 – Inflection Biosciences Ltd, a private company developing innovative therapeutics for cancer, today announced that it has entered into a research collaboration with The University of Texas MD Anderson Cancer Center (“MD Anderson”). The collaboration aims to explore the effects of the company’s pipeline of potential cancer treatments, including its first-in-class, dual mechanism PIM/PI3K inhibitors, in head and neck cancer.

The research will be carried out at the Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, MD Anderson, by Professors Xiuning Le and Maura Gillison. Professor Gillison, a head and neck medical oncologist and molecular epidemiologist, was the first to make the association of human papillomavirus (HPV) in head and neck cancer. She is a leading expert on HPV and oral cancer. Her work also points to a crucial role for PIM and PI3K in the origin and development of certain head and neck cancers.

Dr Michael O’Neill, Director of Research and Development at Inflection Biosciences commented, “We are excited to announce this collaboration with MD Anderson. The team involved in this research are leaders in the field of head and neck cancer research and will enhance our understanding of the potential for our treatments in cancer patients.”

About PIM and PI3K in head and neck cancer

Head and neck cancers are a difficult to treat group of cancers responsible for over 300,000 deaths worldwide each year. Although these are a heterogenous group of cancers, alterations in the function of the PI3K signalling pathway are routinely observed throughout the spectrum of head and neck cancers. Elevated PIM expression is associated with squamous cell carcinomas of the head and neck. High levels of PIM expression have also been found in nasopharyngeal cancer (NPC) cell lines.

About Inflection Biosciences

Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises the IBL-300 series (PIM/PI3K/mTOR inhibitors) and IBL-202 (PIM/PI3K inhibitor) selected from a series of unique dual mechanism kinase inhibitors and the IBL-100 series (selective pan-PIM kinase inhibitors), currently in pre-clinical stages of development. Data generated to date suggests potential application in a range of treatment resistant solid tumours and haematological malignancies. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit

Inflection Biosciences宣布与MD安德森开展合作研究

都柏林--(BUSINESS WIRE)-- (美国商业资讯) -- Inflection Biosciences Ltd是一家开发创新抗癌药的私营公司,该公司今天宣布与德州大学MD安德森癌症中心(简称“MD安德森”)缔结研究合作。该合作旨在探索该公司潜在抗癌药产品线的效应,包括用于头颈部癌的同类首创的双机制PIM/PI3K抑制剂。

该研究将由MD安德森胸科及头颈部肿瘤内科抗癌药组的Xiuning Le和Maura Gillison教授开展。Gillison教授是一位头颈部内科肿瘤学家和分子流行病学家,她首次阐明人类乳头状瘤病毒(HPV)与头颈部癌的关联。她是HPV和口腔癌领域的领先专家。她的研究同时揭示,PIM和PI3K在某些头颈部癌的起源和发展中发挥关键作用。

Inflection Biosciences研发总监Michael O’Neill博士评论道:“宣布与MD安德森合作,我们感到很振奋。该研究团队是头颈部癌研究领域的领先者,将提升对我们对癌症患者治疗潜力的了解。”



关于Inflection Biosciences

Inflection Biosciences Ltd总部位于都柏林和伦敦,正在开发小分子癌症治疗药物。公司的创新抗癌药产品线授权来自西班牙国立癌症研究中心(CNIO)。该产品线包括IBL-300系列(PIM/PI3K/mTOR抑制剂),选自一系列独特的双机制激酶抑制剂的IBL-202(PIM/PI3K抑制剂),以及IBL-100系列(选择性泛PIM激酶抑制剂),目前在临床前开发阶段。欲了解进一步信息,请访问


Darren Cunningham,首席执行官 +353-(0)1-4003615

bottom of page